To include your compound in the COVID-19 Resource Center, submit it here.

After Hong Kong IPO lull, local demand lifts Ascentage offering

Robust local demand helped Ascentage to price its IPO at the top of its proposed range and its shares to rise out of the gate in the second offering after a four-month lapse in listings on the Hong Kong stock exchange’s biotech chapter.

Shares of Suzhou-based Ascentage Pharma Group International (HKSE:6855) gained HK$3.40 (10%) to HK$37.60

Read the full 552 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers